Is it or is it not a pathogenic mutation? Is it or is it not the podocyte?

Journal of Nephropathology

Volumn 1, Issue 3, 2012, Pages 152-154

  Sanchez Niño, Maria Dolores ^a   Ortiz, Alberto ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b Section of Nephrology   (Spain)

Author keywords

Fabry disease; Fabry nephropathy; Kidney disease; Mutation

Indexed keywords

EID: 84874720024     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.5812/nephropathol.8110     Document Type: Note

References (17)

1. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;(105):2812-7.
2. http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GLA; accessed on July 25, 2012.
3. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010 22;5:30.
4. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93(2):112-28.
5. Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant. 2010;25:769-75.
6. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a Kidney Int. 2003;64:801-7.
7. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al.
8. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31-40.
9. Mukdsi JH, Gutiérrez S, Belén Barrón B, Novoa P, Fernández S, De Diller AB, et al. A Renal Variant of Fabry Disease: A case with a novel Gal A hemizygote mutation. J Nephropathology. 2012;1(3):194-7.
10. http://www.rostlab.org/services/snpdbe/dosearch.php?id=name&val=NP_000160&organism2=human&organ ism1=; accessed on July 25, 2012.
11. Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study- -screening genetic conditions in Portuguese young stroke patients. Stroke. 2010;41:431-6.
12. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008;23:1600-7.
13. Najafian B, Svarstad E, Bostad L, Gubler MC, Tøndel C, Whitley C, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 2011;79:663-70.
14. Sanchez-Niño MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011;26:1797-802.
15. Sanchez-Niño MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, et al. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol. 2009;20:353-62.
16. Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol. 2010;5:2220-8.
17. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27:1042-9.